The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.
Anu Acharya, CEO of Ocimum Biosolutions, said: “We have consistently been in the forefront of genomics innovation over many years and this patent reiterates our strong commitment to continue as a leader in this space.”